Expression of Pim-3 in colorectal cancer and its relationship with prognosis

Zhongguo Zhou(Sun Yat-sen University), Zhizhong Pan(Sun Yat-sen University), Ruojing Wang(Sun Yat-sen University), Zhongxi Huang(Sun Yat-sen University), Rongxin Zhang(Guangdong Pharmaceutical University), Jie Zhang(Hebei University of Chinese Medicine), Li Xu(Fujian Medical University), Minshan Chen(Sun Yat-sen University), Jinbin Chen(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University)

Tumor Biology

January 14, 2016

10.1007/s13277-016-4806-7

Cited by 16

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study

|Liver International|2015|1.3k

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

|JAMA Oncology|2019|559

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

|The Lancet|2023|514

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

|Autophagy|2023|387

Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity

|Nature Medicine|2019|367